Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Approval Clears Way For Evolocumab To Blaze Japan PCSK9 Trail

This article was originally published in PharmAsia News

Executive Summary

Following a positive recommendation late last year, Japan has now issued a formal regulatory approval to Amgen Astellas’s evolocumab, which will blaze a trail as the first PCSK9-targeting biologic to be commercialized in the country.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register